Chemomab Therapeutics Ltd. (CMMB)

NASDAQ: CMMB · Real-Time Price · USD

1.640

+0.020 (1.23%)

At close: Nov 20, 2024, 4:00 PM

1.600

-0.040 (-2.44%)

Pre-market: Nov 21, 2024, 7:00 AM EST

Chemomab Therapeutics Employees

Chemomab Therapeutics had 20 employees as of December 31, 2021.

Employees

20

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

-$749,850

Market Cap

23.55M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2021	20	-	-

Related Stocks

Company Name	Employees
Neuronetics	203
Tonix Pharmaceuticals Holding	103
BioXcel Therapeutics	74
PolyPid	62
Equillium	44
Inspira Technologies Oxy B.H.N.	42
NeuroSense Therapeutics	18
AEON Biopharma	10

Employee Rankings

CMMB News

2 days ago - Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis - GlobeNewsWire
3 months ago - Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
3 months ago - Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update - GlobeNewsWire
4 months ago - Chemomab Therapeutics Announces Closing of $10 Million Private Placement - GlobeNewsWire
4 months ago - Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
4 months ago - Chemomab Therapeutics Announces $10 Million Private Placement - GlobeNewsWire
4 months ago - Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis - GlobeNewsWire
6 months ago - Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference - GlobeNewsWire